140 related articles for article (PubMed ID: 37894845)
1. Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas.
Vesterinen T; Peltola E; Leijon H; Hannula P; Huhtala H; Mäkinen MJ; Nieminen L; Pirinen E; Rönty M; Söderström M; Jaatinen P; Arola J
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894845
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical somatostatin receptor expression in insulinomas.
Peltola E; Vesterinen T; Leijon H; Hannula P; Huhtala H; Mäkinen M; Nieminen L; Pirinen E; Rönty M; Söderström M; Arola J; Jaatinen P
APMIS; 2023 Apr; 131(4):152-160. PubMed ID: 36680557
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
4. Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors.
Cases AI; Ohtsuka T; Fujino M; Ideno N; Kozono S; Zhao M; Ohuchida K; Aishima S; Nomura M; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2014 Jan; 43(1):1-6. PubMed ID: 24326362
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
7. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
8. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
9. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
[TBL] [Abstract][Full Text] [Related]
10. Development of an
Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
13. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
14. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys
Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L
Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984
[TBL] [Abstract][Full Text] [Related]
15. Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.
Kondo N; Oishi A; Hirata M; Temma T
Ann Nucl Med; 2021 Jan; 35(1):83-91. PubMed ID: 33067731
[TBL] [Abstract][Full Text] [Related]
16. Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.
Waser B; Reubi JC
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1054-8. PubMed ID: 21210113
[TBL] [Abstract][Full Text] [Related]
17. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results.
Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues.
Dal Molin M; Kim H; Blackford A; Sharma R; Goggins M
Pancreas; 2016 Apr; 45(4):613-9. PubMed ID: 26495786
[TBL] [Abstract][Full Text] [Related]
19. Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer.
Cases AI; Ohtsuka T; Kimura H; Zheng B; Shindo K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Oncol Rep; 2015 Oct; 34(4):1717-25. PubMed ID: 26238361
[TBL] [Abstract][Full Text] [Related]
20. Aggressive versus indolent insulinomas: new clinicopathological insights.
Hackeng WM; Brosens LAA; Dreijerink KMA
Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36779771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
